Citadel Advisors
ROIV icon

Citadel Advisors’s Roivant Sciences ROIV Stock Holding History

Citadel Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.97M Sell
107,100
-210,800
-66% -$5.42M ﹤0.01% 5287
2025
Q4 		$6.9M Buy
317,900
+59,100
+23% +$1.17M ﹤0.01% 3786
2025
Q3 		$3.92M Buy
258,800
+67,600
+35% +$837K ﹤0.01% 4797
2025
Q2 		$2.15M Sell
191,200
-82,200
-30% -$891K ﹤0.01% 5569
2025
Q1 		$2.76M Buy
273,400
+24,300
+10% +$263K ﹤0.01% 4919
2024
Q4 		$2.95M Sell
249,100
-47,900
-16% -$566K ﹤0.01% 4871
2024
Q3 		$3.43M Buy
297,000
+69,000
+30% +$786K ﹤0.01% 4559
2024
Q2 		$2.41M Sell
228,000
-30,700
-12% -$336K ﹤0.01% 4971
2024
Q1 		$2.73M Buy
258,700
+40,400
+19% +$436K ﹤0.01% 4950
2023
Q4 		$2.45M Buy
218,300
+93,100
+74% +$907K ﹤0.01% 5005
2023
Q3 		$1.46M Buy
125,200
+102,500
+452% +$1.16M ﹤0.01% 5820
2023
Q2 		$229K Sell
22,700
-6,300
-22% -$56.4K ﹤0.01% 9583
2023
Q1 		$214K Buy
29,000
+10,700
+58% +$88.1K ﹤0.01% 10070
2022
Q4 		$146K Sell
18,300
-1,200
-6% -$6.67K ﹤0.01% 10649
2022
Q3 		$63K Sell
19,500
-3,200
-14% -$12.4K ﹤0.01% 11465
2022
Q2 		$92K Buy
+22,700
New +$90.1K ﹤0.01% 11493

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ROIV Position: Q1 2026 in Review

Citadel Advisors increased its Roivant Sciences (ROIV) stake by 10% in Q1 2026, buying an estimated $5.91M and bringing the position to 2,515,998 shares worth $69.7M. The position accounts for 0.01% of the portfolio, ranked #1089.

Citadel Advisors first reported a position in ROIV in Q2 2022 and has held it in 16 quarters since. 440 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Citadel Advisors held 2,515,998 shares of Roivant Sciences worth $69.7M as of Q1 2026.
  • Citadel Advisors bought 229,997 Roivant Sciences shares in Q1 2026, an estimated $5.91M.
  • Roivant Sciences made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1089 holding.
  • Citadel Advisors first reported a position in Roivant Sciences in Q2 2022 and has held it in 16 quarters since.
  • 440 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.